Pharming Group Company Insiders
| PHAR Stock | USD 7.53 0.23 2.96% |
Pharming Group employs about 382 people. The company is managed by 12 executives with a total tenure of roughly 892 years, averaging almost 74.0 years of service per executive, having 31.83 employees per reported executive. Discussion of Pharming Group's management performance can provide insight into the enterprise performance.
Pharming |
Pharming Group Management Team Effectiveness
The company has return on total asset (ROA) of (0.0138) % which means that it has lost $0.0138 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0818) %, meaning that it created substantial loss on money invested by shareholders. Pharming Group's management efficiency ratios could be used to measure how well Pharming Group manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/22/2024, Return On Tangible Assets is likely to drop to -0.03. In addition to that, Return On Capital Employed is likely to drop to -0.01. At this time, Pharming Group's Asset Turnover is relatively stable compared to the past year.As of 11/22/2024, Common Stock Shares Outstanding is likely to drop to about 36 M. In addition to that, Net Income Applicable To Common Shares is likely to drop to about 8.3 M
Pharming Group Workforce Comparison
Pharming Group NV is considered to be number one stock in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 1,316. Pharming Group totals roughly 382 in number of employees claiming about 29% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.06) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.05 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.05. Pharming Group Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pharming Group insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pharming Group's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Pharming Group insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Camden Partners Strategic Fund Ii A Lp over three months ago Acquisition by Camden Partners Strategic Fund Ii A Lp of 5000 shares of Pharming Group at 0.68 subject to Rule 16b-3 |
Pharming Group Notable Stakeholders
A Pharming Group stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Pharming Group often face trade-offs trying to please all of them. Pharming Group's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Pharming Group's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| MD MBA | CEO President | Profile | |
| Bruno Giannetti | Consultant | Profile | |
| Susanne Embleton | Investor Manager | Profile | |
| Jeroen Wakkerman | Chief Officer | Profile | |
| Ruud Outersterp | Chief Officer | Profile | |
| Stephen Toor | Chief Americas | Profile | |
| Anurag Relan | Chief Officer | Profile | |
| MBA MD | CEO Pres | Profile | |
| Alexander MBA | Chief Officer | Profile | |
| Mireille MSc | Chief Officer | Profile | |
| Daniela Hanovana | Chief Officer | Profile | |
| MPH MD | Chief Officer | Profile |
About Pharming Group Management Performance
The success or failure of an entity such as Pharming Group NV often depends on how effective the management is. Pharming Group management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Pharming management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Pharming management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.03) | (0.03) | |
| Return On Capital Employed | (0.01) | (0.01) | |
| Return On Assets | (0.02) | (0.02) | |
| Return On Equity | (0.05) | (0.05) |
Pharming Group Workforce Analysis
Traditionally, organizations such as Pharming Group use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Pharming Group within its industry.Pharming Group Manpower Efficiency
Return on Pharming Group Manpower
| Revenue Per Employee | 642.2K | |
| Revenue Per Executive | 20.4M | |
| Net Loss Per Employee | 25K | |
| Net Loss Per Executive | 796.2K | |
| Working Capital Per Employee | 624K | |
| Working Capital Per Executive | 19.9M |
Additional Tools for Pharming Stock Analysis
When running Pharming Group's price analysis, check to measure Pharming Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharming Group is operating at the current time. Most of Pharming Group's value examination focuses on studying past and present price action to predict the probability of Pharming Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharming Group's price. Additionally, you may evaluate how the addition of Pharming Group to your portfolios can decrease your overall portfolio volatility.